Pharming Group (NASDAQ:PHAR – Get Free Report) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 2,800 shares, a decrease of 47.2% from the February 13th total of 5,300 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 7,100 shares, the days-to-cover ratio is presently 0.4 days.
Analyst Ratings Changes
A number of brokerages recently issued reports on PHAR. Jefferies Financial Group started coverage on shares of Pharming Group in a research report on Monday, December 9th. They set a “buy” rating and a $14.00 target price on the stock. Oppenheimer upped their price objective on shares of Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a research report on Friday. Finally, HC Wainwright reissued a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Friday.
Get Our Latest Research Report on Pharming Group
Institutional Investors Weigh In On Pharming Group
Pharming Group Stock Performance
PHAR stock traded up $0.03 during midday trading on Friday, hitting $8.77. The stock had a trading volume of 2,836 shares, compared to its average volume of 6,197. Pharming Group has a 52 week low of $6.65 and a 52 week high of $11.80. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The stock has a 50-day simple moving average of $8.99 and a 200 day simple moving average of $8.58. The firm has a market capitalization of $596.63 million, a price-to-earnings ratio of -33.73 and a beta of -0.10.
Pharming Group (NASDAQ:PHAR – Get Free Report) last issued its earnings results on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.02). The business had revenue of $92.70 million for the quarter, compared to analyst estimates of $76.67 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. As a group, equities research analysts anticipate that Pharming Group will post -0.2 earnings per share for the current year.
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Recommended Stories
- Five stocks we like better than Pharming Group
- The How And Why of Investing in Oil Stocks
- How to Build the Ultimate Everything ETF Portfolio
- Comparing and Trading High PE Ratio Stocks
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.